This page contains a Flash digital edition of a book.
FLIGHTD E P A R TUR E S


TUN3076 BIR457 CAI457 CAN009 BHV56 SAL678 DEL913 GAT3445


DESTINATI ON TUNISIA


MOROCCO EGYPT MEXICO CROATIA BULGARIA INDIA


THE CARIBBEAN


VACCINATION MAY BE ADVISABLE


MAY BE ADVISABLE MAY BE ADVISABLE MAY BE ADVISABLE MAY BE ADVISABLE MAY BE ADVISABLE MAY BE ADVISABLE MAY BE ADVISABLE


ARE THEY REALLY READY TO GO? TICKETS? MONEY? PASSPORTS?


AVAXIM


hepatitis A vaccine (inactivated, adsorbed)


One dose, one visit protection against hepatitis A for their trip


Telephone Customer Service on 0800 085 5511 or ask your Local Vaccine Account Manager. For more information visit VIS online at www.spmsd.com


ABRIDGED PRESCRIBING INFORMATION AVAXIM®


single dose prefi lled , suspension for injection in a prefi lled syringe. Hepatitis A vaccine


(inactivated, adsorbed). Refer to Summary of Product Characteristics for full product information. Presentation: Suspension for injection. Available as a 0.5 millilitre


syringe containing 160 antigen


units of inactivated hepatitis A virus. Indications: For primary or booster immunisation against infection caused by hepatitis A virus in susceptible adults and adolescents aged 16 years and above. Dosage and administration: A single 0.5 millilitre dose should be administered by intramuscular injection in the deltoid region. Immediately before use the syringe should be shaken well to obtain an homogenous suspension. To provide long term protection, a booster should be given between 6 and 36 months later. AVAXIM may be used as a booster in subjects from 16 years of age, vaccinated with another inactivated hepatitis A vaccine (monovalent or with purifi ed Vi polysaccharide typhoid) 6 months to 36 months previously. Contra-indications:


Hypersensitivity to the active substance(s), to any of the excipients or following a previous injection of this vaccine. Known hypersensitivity to neomycin (which may be present in the vaccine in trace amounts). Vaccination should be delayed in subjects with acute severe febrile infections. Warnings and precautions: The effect of AVAXIM on individuals late in the incubation period of hepatitis A has not been documented. Immunogenicity could be impaired in immunosuppressed patients. Caution is advised for the use of AVAXIM in patients with liver disease.


No clinical data on concomitant


administration of AVAXIM with other inactivated vaccine(s) or recombinant hepatitis B virus vaccine have been generated. AVAXIM can also be given at the same time as immunoglobulin but at different sites, however, antibody titres could be lower than after vaccination with AVAXIM alone.


AVAXIM


must not be mixed with other vaccines in the same syringe. AVAXIM can be administered at the same time as Vi polysaccharide typhoid vaccine or with a yellow fever vaccine reconstituted with a Vi polysaccharide typhoid vaccine,


but at different sites. Pregnancy and lactation: AVAXIM should not be used during pregnancy unless clearly necessary and following an assessment of the risks and benefi ts.


There are no data on the effect of administration


of AVAXIM during lactation. AVAXIM is therefore not recommended during lactation. Undesirable effects: Common side effects include: mild local pain, asthenia, myalgia/arthralgia, headache, gastrointestinal tract disorders (nausea, vomiting, decreased appetite, diarrhoea, abdominal pain) and mild fever.


®


For a complete list of undesirable effects please refer to the Summary of Product Characteristics. Package quantities and basic NHS cost: Single dose prefi lled syringes in single packs, basic NHS cost £18.10; packs of 10 single dose prefi lled syringes, basic NHS cost £181.00. Marketing authorisation holder: Sanofi Pasteur MSD Limited, Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 1QP. Marketing authorisation number: PL 6745/0070. Legal category: POM ® Registered Trademark Date of last review: January 2010


YOUR ONE STOP TRAVEL SHOP


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Sanofi Pasteur MSD, telephone number 01628 785291.


UK15470 02/12


AVAXIM® - available to order now





Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84